The signing ceremony of a Memorandum of Understanding between the Indian company MSN Laboratories Pvt. Ltd., LLP “Kazakh Pharmaceutical Company MEDSERVICE PLUS,” and JSC “NC “KAZAKH INVEST” took place at the office of KAZAKH INVEST. The document provides for the implementation of a joint investment project to establish a full-cycle pharmaceutical plant in the Almaty region.
During the event, the parties discussed the details of the planned production, which will focus on the manufacture of solid dosage forms for both the domestic market and export. The project envisions full localization, covering everything from development and manufacturing to packaging and distribution of pharmaceuticals. The investment volume will exceed $58.8 million, and once the plant reaches full capacity, more than 300 jobs will be created for Kazakhstan’s citizens.
The signing of the Memorandum is the result of consistent efforts to attract foreign direct investment into the healthcare and pharmaceutical sectors. The new plant is expected to contribute to achieving the national goal of increasing the share of locally produced pharmaceuticals to 50%.
Speaking at the meeting, Azamat Kozhanov, Deputy Chairman of the Board of KAZAKH INVEST, noted:
“We view this project as an important element in developing Kazakhstan’s industrial base. This is not just a manufacturing facility, but a platform for technology transfer, workforce skill enhancement, and the expansion of the industry’s export potential. The implementation of this initiative aligns with the country’s industrialization priorities and the goal of increasing the share of local production in the pharmaceutical sector. On our part, the national company KAZAKH INVEST will provide comprehensive support at every stage — from project initiation to full-scale plant operations.”
On behalf of the foreign partner, the Head of MSN Laboratories’ representative office in Kazakhstan, U. V. R. V. Prasad, expressed strong interest in the company’s long-term presence in the region:
“We are confident that establishing a modern and advanced manufacturing facility in Kazakhstan will enable the localization of high-tech and complex pharmaceuticals, meeting the needs of national healthcare and opening opportunities for export to CIS countries. The plant will produce a wide range of medicines, including treatments for oncological diseases, with access to our global portfolio, which is continuously expanding and includes innovative solutions across various therapeutic areas.”
In turn, Yuri Kan, Deputy Chairman of the Board of LLP "Kazakh Pharmaceutical Company MEDSERVICE PLUS," emphasized the strategic significance of the project:
“The implementation of this project is an important step both for our company and for the entire pharmaceutical industry of Kazakhstan. Investment in pharmaceutical technologies by a Kazakh company is a strategic contribution to the country’s future, as the technologies will remain in Kazakhstan. We are confident that cooperation with MSN Laboratories will provide access to advanced technologies, available active pharmaceutical ingredients (APIs), and effective, high-quality medicines. An important aspect is the program for creating new jobs, training, mentoring, and upgrading the qualifications of local specialists to an international level.”
The implementation of the project will be a significant step in the development of Kazakhstan’s pharmaceutical industry — strengthening the production and export base, reducing import dependence, and advancing the achievement of the national goal.
